These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
952 related articles for article (PubMed ID: 30536063)
21. Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment. Gomez A; Ferrer I Acta Neuropathol; 2010 Aug; 120(2):155-67. PubMed ID: 20232069 [TBL] [Abstract][Full Text] [Related]
22. The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A. Rivero-Ríos P; Romo-Lozano M; Madero-Pérez J; Thomas AP; Biosa A; Greggio E; Hilfiker S J Biol Chem; 2019 Mar; 294(13):4738-4758. PubMed ID: 30709905 [TBL] [Abstract][Full Text] [Related]
23. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation. Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589 [TBL] [Abstract][Full Text] [Related]
24. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons. López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501 [TBL] [Abstract][Full Text] [Related]
25. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology. Xiong Y; Neifert S; Karuppagounder SS; Stankowski JN; Lee BD; Grima JC; Chen G; Ko HS; Lee Y; Swing D; Tessarollo L; Dawson TM; Dawson VL eNeuro; 2017; 4(2):. PubMed ID: 28321439 [TBL] [Abstract][Full Text] [Related]
26. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. Gaig C; Martí MJ; Ezquerra M; Rey MJ; Cardozo A; Tolosa E J Neurol Neurosurg Psychiatry; 2007 Jun; 78(6):626-8. PubMed ID: 17210620 [TBL] [Abstract][Full Text] [Related]
27. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression. Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043 [TBL] [Abstract][Full Text] [Related]
28. Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study. Mestre TA; Pont-Sunyer C; Kausar F; Visanji NP; Ghate T; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Kasten M; Wadia PM; Zadikoff C; Kumar P; de Bie RM; Thomsen T; Lang AE; Schüle B; Klein C; Tolosa E; Marras C Mov Disord; 2018 Jul; 33(6):960-965. PubMed ID: 29665080 [TBL] [Abstract][Full Text] [Related]
29. α-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain. Fernández-Santiago R; Garrido A; Infante J; González-Aramburu I; Sierra M; Fernández M; Valldeoriola F; Muñoz E; Compta Y; Martí MJ; Ríos J; Tolosa E; Ezquerra M; Mov Disord; 2018 Apr; 33(4):637-641. PubMed ID: 29473656 [TBL] [Abstract][Full Text] [Related]
30. Pathological Functions of LRRK2 in Parkinson's Disease. Jeong GR; Lee BD Cells; 2020 Nov; 9(12):. PubMed ID: 33266247 [TBL] [Abstract][Full Text] [Related]
32. Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease. Elliott DA; Kim WS; Gorissen S; Halliday GM; Kwok JB Mov Disord; 2012 Jul; 27(8):1004-11. PubMed ID: 22528366 [TBL] [Abstract][Full Text] [Related]
33. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology. Mamais A; Manzoni C; Nazish I; Arber C; Sonustun B; Wray S; Warner TT; Cookson MR; Lewis PA; Bandopadhyay R Brain Res; 2018 Dec; 1701():75-84. PubMed ID: 30055128 [TBL] [Abstract][Full Text] [Related]
34. G2019S LRRK2 mutant fibroblasts from Parkinson's disease patients show increased sensitivity to neurotoxin 1-methyl-4-phenylpyridinium dependent of autophagy. Yakhine-Diop SM; Bravo-San Pedro JM; Gómez-Sánchez R; Pizarro-Estrella E; Rodríguez-Arribas M; Climent V; Aiastui A; López de Munain A; Fuentes JM; González-Polo RA Toxicology; 2014 Oct; 324():1-9. PubMed ID: 25017139 [TBL] [Abstract][Full Text] [Related]
35. SNCA but not DNM3 and GAK modifies age at onset of LRRK2-related Parkinson's disease in Chinese population. Yang ZH; Li YS; Shi MM; Yang J; Liu YT; Mao CY; Fan Y; Hu XC; Shi CH; Xu YM J Neurol; 2019 Jul; 266(7):1796-1800. PubMed ID: 31041581 [TBL] [Abstract][Full Text] [Related]
36. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease. Daher JP Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation. Su YC; Qi X Hum Mol Genet; 2013 Nov; 22(22):4545-61. PubMed ID: 23813973 [TBL] [Abstract][Full Text] [Related]
38. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia. Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990 [TBL] [Abstract][Full Text] [Related]
39. LRRK2 impairs autophagy by mediating phosphorylation of leucyl-tRNA synthetase. Ho DH; Kim H; Nam D; Sim H; Kim J; Kim HG; Son I; Seol W Cell Biochem Funct; 2018 Dec; 36(8):431-442. PubMed ID: 30411383 [TBL] [Abstract][Full Text] [Related]
40. Altered Motor Performance, Sleep EEG, and Parkinson's Disease Pathology Induced by Chronic Sleep Deprivation in Lrrk2 Liu X; Yu H; Wang Y; Li S; Cheng C; Al-Nusaif M; Le W Neurosci Bull; 2022 Oct; 38(10):1170-1182. PubMed ID: 35612787 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]